Neurodegeneration in mitochondrial disorders

Phillips, J; Hayhurst, H; Lax, NZ

doi:10.1007/978-3-319-28637-2_2

Neurodegeneration in mitochondrial disorders

Lookup NU author(s): Jonathan Phillips, Dr Hannah Hayhurst, Dr Nichola Lax

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© Springer International Publishing 2016. All rights reserved. Mitochondria are critically responsible for the generation of energy in the form of adenine triphosphate (ATP) through the mitochondrial respiratory chain (see Chap. 1). The central nervous system (CNS) performs highly energy-intensive tasks and is therefore particularly dependent on ATP. Defects residing within the complexes of the respiratory chain can affect the synthesis of ATP and consequently severely compromise neuronal function. It is unsurprising then that mitochondrial DNA (mtDNA) defects are an important cause of neurological disease. The clinical presentation is often heterogeneous in terms of age of onset and different neurological signs and symptoms which might include ataxia, seizures, cognitive decline, blindness and stroke-like episodes. The clinical course can vary considerably, but in many patients there are progressive neurological decline and marked neurodegeneration. Our understanding of the mechanisms underpinning neurodegenerative changes due to mitochondrial DNA defects is limited due to the availability of appropriate animal models of disease. However, studies on human post-mortem CNS tissues have provided an invaluable insight into the distribution and severity of neuronal degeneration in patients harbouring mitochondrial DNA defects. In this chapter, we describe the neuropathological changes occurring in the CNS associated with different mutations of the mitochondrial genome and discuss the mechanisms which might contribute to neural dysfunction and cell death.